Cognitive & Nootropic / Level D / Early Research / Last reviewed 2026-08-27

N-Acetyl Selank Evidence Guide

Evidence for N-Acetyl Selank is too preliminary to support a research protocol with confidence. There are no independent clinical trials for this modified form of Selank. Even the parent compound Selank has only Russian-sourced data. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has substantially more independently replicated human trial data.

Our Take

Evidence context: Modified anxiolytic peptide mechanistic research (no independent clinical data)
Evidence grade: Level D
Confidence: Low
Reference context: Reported research reference: No established human protocol with independent validation

Benefits and Evidence

Anxiolytic Effect (extrapolated from Selank): Level D, mostly non-human evidence - Based on Selank research, the acetylated form is expected to reduce anxiety-like behaviors through GABA-A receptor modulation, though direct human studies on N-Acetyl Selank specifically are absent.
Peptide Stability Enhancement: Level D, mostly non-human evidence - N-terminal acetylation is a well-established approach to improve peptide stability against aminopeptidases, expected to extend biological half-life compared to unmodified Selank.
Cognitive Enhancement (extrapolated): Level D, mostly non-human evidence - Extrapolated from Selank data showing enhanced memory consolidation and BDNF upregulation in rodent models. Direct evidence for N-Acetyl Selank is minimal.

Side Effects and Warnings

Fatigue (extrapolated from Selank)
Nasal irritation (intranasal)
Mild sedation
Headache (rare)
No direct human clinical trials exist for N-Acetyl Selank
Efficacy and safety data are extrapolated from Selank research
The modification may alter pharmacological properties in unpredictable ways
Not approved for medical use in any country

Research Dosage References

<strong>Intranasal</strong> - 200-600 mcg - Once or twice daily - Dosing extrapolated from Selank intranasal protocols. No specific clinical dosing for N-Acetyl Selank has been established.
<strong>Subcutaneous</strong> - 250-500 mcg - Once daily - Subcutaneous administration used by researchers. Bioavailability may be superior to intranasal route.

Mechanism of Action

N-Acetyl Selank is expected to share Selank's primary mechanisms: (1) Allosteric modulation of GABA-A receptors, enhancing GABAergic inhibitory tone to produce anxiolytic effects; (2) Upregulation of BDNF mRNA expression in hippocampal neurons, promoting synaptic plasticity and cognitive function; (3) Modulation of IL-6, interferon, and other cytokine expression via tuftsin-like immunomodulatory activity; (4) Influence on serotonin and dopamine metabolism in prefrontal cortex and hippocampus. The acetyl group primarily enhances metabolic stability without altering the core pharmacological profile.

Legal Status

Unregulated research peptide in most countries.

Primary Sources

Anxiolytic-like effect of Selank and its metabolic stability. Bulletin of Experimental Biology and Medicine, 2003.
The effect of Selank on BDNF gene expression in the rat hippocampus. Doklady Biological Sciences, 2008.

Quick Answers

Where is the strongest evidence for N-Acetyl Selank?

What are the main side effects of N-Acetyl Selank?

N-Acetyl Selank side effects and warning signals include Fatigue (extrapolated from Selank), Nasal irritation (intranasal), Mild sedation, Headache (rare), and No direct human clinical trials exist for N-Acetyl Selank.

What evidence level is N-Acetyl Selank?

N-Acetyl Selank is rated Level D; the listed research status is Early Research.